Table 3

Minimal clinically important improvement estimates for individual and composite rheumatoid arthritis activity measures, using a specificity of 0.80 as the criterion

MeasureROC curve area (95% CI)MCII (95% CI)Sensitivity (95% CI)Percent misclassified (95% CI)
Patient global assessment0.74 (0.68 to 0.80)−18.4 (−26.0 to −12.0)0.58 (0.39 to 0.72)34.6 (30.0 to 39.1)
Pain0.76 (0.69 to 0.82)−20.4 (−24.0 to −17.1)0.61 (0.50 to 0.74)33.3 (30.3 to 39.4)
HAQ0.79 (0.73 to 0.85)−0.375 (−0.5 to −0.25)0.62 (0.55 to 0.74)28.8 (23.4 to 34.8)
DAS28-ESR0.77 (0.71 to 0.82)−1.17 (−1.36 to −0.87)0.62 (0.48 to 0.72)34.9 (30.4 to 39.3)
DAS28-CRP0.79 (0.73 to 0.84)−1.02 (−1.44 to −0.83)0.64 (0.43 to 0.76)32.4 (27.0 to 36.3)
SDAI0.78 (0.73 to 0.84)−13.1 (−17.5 to −10.7)0.63 (0.37 to 0.76)32.1 (27.5 to 36.7)
CDAI0.78 (0.73 to 0.84)−12.5 (−14.7 to −10.5)0.63 (0.47 to 0.75)30.9 (27.2 to 36.3)
  • *Values are means of 2000 bootstrapped samples.

  • †Median (5th, 95th percentile).

  • CDAI, Clinical Disease Activity Index; DAS28-CRP, Disease Activity Score 28 C-reactive Protein; DAS28-ESR, Disease Activity Score 28 Erythrocyte Sedimentation Rate; HAQ, Health Assessment Questionnaire Disability Index; MCII, minimal clinically important improvement; ROC, receiver operating characteristic; SDAI, Simplified Disease Activity Index.